Ratings by Leerink (Roanna Ruiz)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/13/2026 | Kardigan Inc | KARD | New Coverage | Outperform (N/A) |
24.64 (21.13) |
-14.25% | Details | |
| 4/21/2026 | Trevi Therapeutics | TRVI | Maintain | Outperform (N/A) |
|
Details | ||
| 4/14/2026 | Akebia Therapeutics | AKBA | Maintain | Outperform (N/A) |
|
Details | ||
| 4/13/2026 | MannKind | MNKD | Maintain | Outperform (N/A) |
|
Details | ||
| 3/26/2026 | iBio, Inc. | IBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 3/12/2026 | Ardelyx, Inc | ARDX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/10/2026 | Cytokinetics | CYTK | Maintain | Outperform (N/A) |
|
Details | ||
| 3/10/2026 | ARS Pharmaceuticals Inc | SPRY | Maintain | Outperform (N/A) |
|
Details | ||
| 3/6/2026 | CorMedix | CRMD | Maintain | Outperform (N/A) |
|
Details | ||
| 3/2/2026 | United Therapeutics Corp. | UTHR | Maintain | Outperform (N/A) |
|
Details | ||
| 2/26/2026 | Vir Biotechnology | VIR | Maintain | Outperform (N/A) |
|
Details | ||
| 2/2/2026 | Trevi Therapeutics | TRVI | Maintain | Outperform (N/A) |
|
Details | ||
| 1/12/2026 | CorMedix | CRMD | Maintain | Outperform (N/A) |
|
Details | ||
| 1/6/2026 | NewAmsterdam Pharma Co NV | NAMS | Maintain | Outperform (N/A) |
|
Details | ||
| 12/9/2025 | MannKind | MNKD | Maintain | Outperform (N/A) |
|
Details | ||
| 12/9/2025 | Vir Biotechnology | VIR | Maintain | Outperform (N/A) |
|
Details | ||
| 11/19/2025 | Trevi Therapeutics | TRVI | Maintain | Outperform (N/A) |
|
Details | ||
| 11/13/2025 | Trevi Therapeutics | TRVI | New Coverage | Outperform (N/A) |
11.85 (19.07) |
60.93% | Details | |
| 11/13/2025 | Contineum Therapeutics | CTNM | New Coverage | Outperform (N/A) |
11.47 (14.23) |
24.06% | Details | |
| 11/13/2025 | MannKind | MNKD | New Coverage | Outperform (N/A) |
5.25 (4.03) |
-23.24% | Details | |
| 11/6/2025 | NewAmsterdam Pharma Co NV | NAMS | Maintain | Outperform (N/A) |
|
Details | ||
| 10/30/2025 | Amarin Corporation | AMRN | Maintain | Market Perform (N/A) |
|
Details | ||
| 10/17/2025 | iBio, Inc. | IBIO | New Coverage | Outperform (N/A) |
0.85 (1.38) |
62.35% | Details | |
| 9/30/2025 | Enanta Pharmaceuticals | ENTA | Maintain | Market Perform (N/A) |
|
Details | ||
| 9/23/2025 | CorMedix | CRMD | Maintain | Outperform (N/A) |
|
Details | ||
| 8/19/2025 | Xeris Pharmaceuticals | XERS | Maintain | Outperform (N/A) |
|
Details | ||
| 6/5/2025 | Xeris Pharmaceuticals | XERS | Maintain | Outperform (N/A) |
|
Details | ||
| 6/4/2025 | United Therapeutics Corp. | UTHR | Maintain | Outperform (N/A) |
|
Details | ||
| 4/28/2025 | Akebia Therapeutics | AKBA | New Coverage | Outperform (N/A) |
2.38 (1.34) |
-43.7% | Details | |
| 3/7/2025 | CorMedix | CRMD | New Coverage | Outperform (N/A) |
9.49 (8.42) |
-11.28% | Details | |
| 3/5/2025 | Lexicon Pharmaceuticals | LXRX | Downgrade | Market Perform (Outperform) |
0.29 (2.39) |
724.14% | Details | |
| 3/3/2025 | Aquestive Therapeutics | AQST | Maintain | Outperform (N/A) |
|
Details | ||
| 2/19/2025 | Aquestive Therapeutics | AQST | Maintain | Outperform (N/A) |
|
Details | ||
| 11/26/2024 | Enanta Pharmaceuticals | ENTA | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/20/2024 | NewAmsterdam Pharma Co NV | NAMS | Maintain | Outperform (N/A) |
|
Details | ||
| 11/1/2024 | Lexicon Pharmaceuticals | LXRX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/25/2024 | Aquestive Therapeutics | AQST | Maintain | Outperform (N/A) |
|
Details | ||
| 10/18/2024 | Lexicon Pharmaceuticals | LXRX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/10/2024 | Aquestive Therapeutics | AQST | New Coverage | Outperform (N/A) |
3.29 (4.12) |
25.23% | Details | |
| 4/5/2024 | Ardelyx, Inc | ARDX | New Coverage | Outperform (N/A) |
7.16 (5.20) |
-27.37% | Details | |
| 3/5/2024 | ARS Pharmaceuticals Inc | SPRY | Upgrade | Outperform (Market Perform) |
8.65 (7.00) |
-19.08% | Details | |
| 2/5/2024 | United Therapeutics Corp. | UTHR | New Coverage | Outperform (N/A) |
213.41 (535.67) |
151.01% | Details | |
| 1/5/2024 | Vir Biotechnology | VIR | Maintain | Outperform (N/A) |
|
Details | ||
| 9/21/2023 | ARS Pharmaceuticals Inc | SPRY | Downgrade | Market Perform (Outperform) |
2.92 (7.00) |
139.73% | Details | |
| 8/15/2023 | Cytokinetics | CYTK | New Coverage | Outperform (N/A) |
32.10 (80.18) |
149.78% | Details | |
| 4/11/2023 | Corcept Therapeutics | CORT | New Coverage | Market Perform (N/A) |
22.63 (90.52) |
300% | Details | |
| 4/4/2023 | Pardes Biosciences | PRDS | Downgrade | Market Perform (Outperform) |
1.32 (2.16) |
63.64% | Details | |
| 12/20/2022 | NewAmsterdam Pharma Co NV | NAMS | New Coverage | Outperform (N/A) |
11.31 (31.68) |
180.11% | Details | |
| 10/24/2022 | Myovant Sciences Ltd. | MYOV | Downgrade | Market Perform (Outperform) |
24.54 (26.98) |
9.94% | Details | |
| 10/11/2022 | scPharmaceuticals | SCPH | Upgrade | Outperform (Market Perform) |
4.02 (5.67) |
41.04% | Details | |
| 9/14/2022 | Vir Biotechnology | VIR | New Coverage | Outperform (N/A) |
20.57 (9.43) |
-54.16% | Details | |
| 8/9/2022 | Myovant Sciences Ltd. | MYOV | Upgrade | Outperform (Market Perform) |
15.67 (26.98) |
72.18% | Details | |
| 7/14/2022 | ContraFect Corp. | CFRX | Downgrade | Market Perform (Outperform) |
2.85 (0.23) |
-91.93% | Details | |
| 5/19/2022 | Enanta Pharmaceuticals | ENTA | Maintain | Market Perform (N/A) |
|
Details | ||
| 5/5/2022 | Aligos Therapeutics Inc. | ALGS | Downgrade | Market Perform (Outperform) |
1.24 (5.74) |
362.9% | Details | |
| 5/5/2022 | Amarin Corporation | AMRN | Downgrade | Market Perform (Outperform) |
1.56 (13.94) |
793.59% | Details | |
| 3/15/2022 | Pardes Biosciences | PRDS | New Coverage | Outperform (N/A) |
5.64 (2.16) |
-61.7% | Details | |
| 3/11/2022 | Aligos Therapeutics Inc. | ALGS | Maintain | Outperform (N/A) |
|
Details | ||
| 1/31/2022 | Amarin Corporation | AMRN | Maintain | Outperform (N/A) |
|
Details | ||
| 12/31/2021 | Xeris Pharmaceuticals | XERS | Maintain | Outperform (N/A) |
|
Details | ||
| 11/18/2021 | Atea Pharmaceuticals | AVIR | Downgrade | Market Perform (Outperform) |
8.69 (4.87) |
-43.96% | Details | |
| 11/17/2021 | Xeris Pharmaceuticals | XERS | New Coverage | Outperform (N/A) |
2.39 (8.80) |
268.2% | Details | |
| 9/9/2021 | Atea Pharmaceuticals | AVIR | New Coverage | Outperform (N/A) |
27.70 (4.87) |
-82.42% | Details | |
| 9/9/2021 | Amarin Corporation | AMRN | New Coverage | Outperform (N/A) |
5.15 (13.94) |
170.68% | Details | |
| 9/9/2021 | Myovant Sciences Ltd. | MYOV | New Coverage | Market Perform (N/A) |
25.81 (26.98) |
4.53% | Details | |
| 9/9/2021 | Aligos Therapeutics Inc. | ALGS | New Coverage | Outperform (N/A) |
15.31 (5.74) |
-62.51% | Details | |
| 9/9/2021 | ContraFect Corp. | CFRX | New Coverage | Outperform (N/A) |
3.90 (0.23) |
-94.1% | Details | |
| 9/9/2021 | Enanta Pharmaceuticals | ENTA | New Coverage | Market Perform (N/A) |
57.17 (13.74) |
-75.97% | Details | |
| 9/9/2021 | scPharmaceuticals | SCPH | New Coverage | Market Perform (N/A) |
5.95 (4.02) |
-32.44% | Details |
